Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 12/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.77 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.75 |
| ▸ | STK10 | O94804 | 2/20 | 0.75 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.75 |
| ▸ | RET | P07949 | 2/20 | 0.75 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.75 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.75 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.75 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.75 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.75 |
| ▸ | ABL1 | P00519 | 1/20 | 0.75 |
| ▸ | EGFR | P00533 | 1/20 | 0.75 |
| ▸ | LCK | P06239 | 1/20 | 0.75 |
| ▸ | CSF1R | P07333 | 1/20 | 0.75 |
| ▸ | HCK | P08631 | 1/20 | 0.75 |
| ▸ | KIT | P10721 | 1/20 | 0.75 |
| ▸ | SRC | P12931 | 1/20 | 0.75 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1227548 | 0.92 | KDR (0.77) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1227649 | 0.91 | KDR (0.76) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL12899428 | 0.91 | KDR (0.79) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1227552 | 0.91 | KDR (0.77) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1227526 | 0.91 | KDR (0.78) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL3451491 | 0.91 | KDR (0.78) | KDRCYP3A4KCNH2FGFR1STK10 | |
| Methane SCHEMBL5605672 | 0.91 | KDR (0.75) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1226909 | 0.90 | KDR (0.79) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1226919 | 0.90 | KDR (0.74) | KDRCYP3A4KCNH2FGFR1STK10 | |
| SCHEMBL1227708 | 0.89 | KDR (0.75) | KDRCYP3A4KCNH2FGFR1STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212679-A1 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-07-06 | — | — | US | disclosed |
| CN-115836054-A | IL4I1 inhibitors and methods of use | 默沙东有限责任公司 | 2023-03-21 | — | — | CN | disclosed |
| EP-2663283-B1 | HIGH DRUG LOAD TABLET FORMULATION OF BRIVANIB ALANINATE | BRISTOL MYERS SQUIBB CO (US) | 2017-05-10 | — | — | EP | disclosed |
| US-20130236483-A1 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY | BUSH ANDREW B (US) | 2013-09-12 | — | — | US | disclosed |
| EP-2010538-B1 | PROCESS FOR THE PREPARATION OF Ý(1R), 2S¨-2-AMINOPROPIONIC ACID 2-Ý4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLOÝ2,1-f¨Ý1,2,4¨TRIAZIN-6-YLOXY¨-1-METHYLETHYL ESTER | BRISTOL MYERS SQUIBB CO (US) | 2012-12-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212679-A1 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | VEGFA, BRAF, FLT4 | KDR 4/4885CYP3A4 4446/4885KCNH2 4658/4885 |
| US-20130236483-A1 | FGF MODULATION OF IN VIVO ANTIBODY PRODUCTION AND HUMORAL IMMUNITY | FGF2, FGF1, FGFR2 | KDR 130/4885CYP3A4 4861/4885KCNH2 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.